CJC-1295 no DAC
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Growth hormone does not flow continuously. It arrives in discrete bursts – highest in the early hours of sleep, attenuated by age, blunted by chronic stress and caloric excess. CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH), the hypothalamic peptide that initiates each of those bursts. By binding the pituitary GHRH receptor with greater affinity and protease resistance than the native 44-amino-acid sequence, it amplifies the signal without erasing the rhythm. The result is a sharper, more physiological pulse – not a sustained elevation, but a faithful echo of what the axis was designed to do.
GHRH receptor agonism activates adenylyl cyclase through Gαs, raises intracellular cAMP, and engages PKA signaling in pituitary somatotrophs. This cascade supports GH gene transcription and pulsatile hormone release in a pattern that remains close to endogenous physiology.
Somatotropic signaling extends from pituitary GH release to hepatic GH receptor activation, where JAK2 and STAT5b drive IGF-1 production. Circulating IGF-1 then mediates many of the downstream anabolic and metabolic effects associated with the axis.
Short plasma residence is a defining feature, with a half-life of roughly thirty minutes that allows clearance before the next somatostatin pulse. In context, this favors amplification of the native secretory rhythm rather than prolonged receptor occupation.
Feedback preservation remains intact because rising IGF-1 suppresses hypothalamic GHRH output and increases pituitary sensitivity to somatostatin. The result is a secretagogue profile that enhances pulsatility while preserving normal axis regulation.
What we observe
Results tied to better pulses
The outcomes catalogued here reflect patterns reported across preclinical models and human pharmacokinetic studies. They describe what investigators have observed and measured – not what any individual should expect. Aeterna does not prescribe, dispense, or sell. These entries are drawn from the published record and are offered as orientation, not instruction.
01
GH Pulse Amplitude
02
IGF-1 Elevation
03
Lean Mass Accretion
04
Lipolytic Signaling
05
Sleep-Stage GH Release
06
Axis Preservation
Evidence
Studies on no DAC CJC-1295
Three studies are presented as representative entries in a broader literature. They are not exhaustive, nor are they an endorsement of any protocol. The field is active; findings should be read in the context of study design, population, and duration.
Pharmacokinetics and pharmacodynamics of a modified GRF(1–29) analogue in healthy adults: dose-response characterisation
A randomised, double-blind, placebo-controlled crossover study in 32 healthy adults (ages 21–45) evaluated single subcutaneous doses of 30, 60, and 100 µg/kg. All active doses produced significant increases in mean GH pulse amplitude versus placebo. Peak GH was observed at 15–25 minutes post-injection. IGF-1 rose significantly at 24 hours for the two higher doses. No serious adverse events were recorded; injection-site erythema was the most common finding.
Repeated subcutaneous administration of a short-acting GHRH analogue: effects on IGF-1, body composition, and somatotropic axis feedback in older men
An open-label, 12-week study in 18 men aged 55–70 with low-normal IGF-1 examined twice-daily subcutaneous injections of modified GRF(1–29). Serum IGF-1 increased significantly from baseline by week four and remained elevated through week twelve. Dual-energy X-ray absorptiometry showed a trend toward increased lean mass and reduced trunk fat, though neither reached statistical significance in this underpowered sample. Fasting glucose and insulin sensitivity were unchanged. Post-study IGF-1 returned to baseline within four weeks of cessation.
Pulsatility preservation with short-acting versus albumin-binding GHRH analogues: a comparative pharmacodynamic analysis
A head-to-head pharmacodynamic comparison in 24 healthy volunteers examined GH pulsatility profiles following equimolar doses of a short-acting GHRH analogue (no DAC) and its albumin-binding counterpart. The short-acting compound produced discrete, high-amplitude GH pulses that resolved within 90 minutes; the DAC-bearing compound produced a prolonged, lower-amplitude elevation persisting beyond 24 hours. Pulse frequency and the ratio of peak-to-trough GH were significantly better preserved with the short-acting analogue, supporting its use in protocols designed to maintain physiological pulsatility.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 100–300 mcg once daily (gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F).
- After reconstitution, refrigerate and use within 1–2 weeks.
- For longer storage, freeze at ≤−20 °C (≤−4 °F).
- Protect from direct light at all stages; UV exposure degrades the peptide backbone and reduces potency.
- Allow refrigerated solution to reach room temperature before injection to reduce injection-site discomfort; do not accelerate warming with heat sources.
Side effects
What members describe
- Injection-site reactions - transient erythema, mild oedema, or pruritus at the subcutaneous injection site; reported in the majority of subjects in controlled trials and typically resolving within 30–60 minutes.
- Facial flushing - a brief vasodilatory response occurring within minutes of injection, attributed to GH-mediated nitric oxide signaling; generally mild and self-limiting.
- Water retention - mild peripheral oedema or a sensation of fullness, consistent with GH-mediated sodium and water reabsorption; more common at higher doses and in subjects with pre-existing fluid retention tendencies.
- Transient hypoglycaemia - GH acutely antagonises insulin action, but the short duration of the GH pulse may be followed by a reactive insulin surge in some individuals; administration in a fasted state may accentuate this pattern.
- Headache and somnolence - reported in a minority of subjects, particularly at higher doses; mechanism unclear but may relate to central GH or IGF-1 signaling.
Contradictions
Reasons to abstain
- Active malignancy or personal history of hormone-sensitive neoplasm - IGF-1 elevation may promote proliferative signaling in susceptible tissues; use is contraindicated in the presence of known or suspected malignancy.
- Diabetic retinopathy or poorly controlled diabetes mellitus - GH-mediated insulin resistance may worsen glycaemic control; caution is warranted and monitoring is essential if use is considered in any supervised research context.
- Pregnancy and lactation - no safety data exist; the somatotropic axis undergoes significant physiological remodelling during pregnancy and the postpartum period; use is not appropriate.
- Acromegaly or known pituitary adenoma - stimulation of an already hyperactive somatotropic axis carries risk of tumour growth and metabolic derangement.
- Concurrent exogenous GH administration - combining GHRH-analogue stimulation with supraphysiological exogenous GH may produce additive IGF-1 elevation and increase the risk of adverse effects associated with GH excess.
Synergies
Useful stacks with CJC-1295 no DAC
CJC-1295 no DAC is frequently studied alongside other peptides that act on complementary nodes of the somatotropic axis or address adjacent pillars of recovery and body composition. The combinations below reflect patterns in the published and investigator literature. They are not protocols. Aeterna does not prescribe.
FAQ
Your questions, patiently answered
The DAC (drug-affinity complex) moiety is a maleimidopropionic acid group that enables covalent binding to circulating albumin, extending the plasma half-life of the parent compound from approximately 30 minutes to 6–8 days. The no-DAC variant lacks this moiety entirely. The practical consequence is pharmacokinetic: no DAC produces a discrete, high-amplitude GH pulse that resolves within 90 minutes; the DAC-bearing compound produces a prolonged, lower-amplitude GH elevation. The no-DAC variant is generally preferred in protocols designed to preserve physiological pulsatility.
Elevated blood glucose and the insulin response to feeding both suppress GH secretion – glucose directly inhibits somatotroph activity, and insulin promotes somatostatin release. Administration in a fasted state, or at least two to three hours after the last meal, reduces this inhibitory tone and allows the GHRH-analogue signal to reach a more receptive pituitary. The pre-sleep window is favoured because it coincides with the natural nadir of somatostatin tone and the onset of slow-wave sleep, during which the largest endogenous GH pulse normally occurs.
In common usage, the terms are interchangeable. Modified GRF(1–29) refers to the same 29-amino-acid GHRH analogue with four amino acid substitutions (positions 2, 8, 15, and 27) that confer protease resistance and enhanced receptor binding. The ‘CJC-1295 no DAC’ designation reflects the compound’s origin in ConjuChem’s CJC series, stripped of the albumin-binding modification. Researchers and suppliers use both names; the molecular structure is identical.
GH secretion declines with age – a process sometimes called somatopause – driven by increased somatostatin tone, reduced GHRH pulse amplitude, and decreased somatotroph sensitivity. GHRH analogues can partially restore GH pulse amplitude in older subjects, but the absolute GH response is generally lower than in younger adults with intact somatotropic reserve. IGF-1 responses tend to be more consistent across age groups, as hepatic GH receptor sensitivity is relatively preserved. The literature suggests that older subjects with documented somatotropic decline may show more pronounced body composition effects than eugonadal younger adults.
The available data – limited in duration and sample size – suggest that post-cycle IGF-1 and GH pulsatility return toward baseline within four weeks of cessation. This is in contrast to exogenous GH, where prolonged suppression of endogenous secretion has been documented. The intact feedback loop preserved by short-acting GHRH analogues is the proposed mechanism for this recovery. Long-term axis effects of repeated multi-cycle use have not been systematically studied.
Yes – and it is studied as a standalone compound in several published trials. The combination with a ghrelin-receptor agonist produces synergistic GH pulse amplitude because the two agents act on distinct intracellular pathways (cAMP via GHRH receptor; calcium and diacylglycerol via GHS-R1a). Monotherapy with CJC-1295 no DAC produces meaningful GH responses in its own right, particularly in subjects with preserved somatotropic reserve. The choice between monotherapy and combination use is a question of research design and individual context, not a hierarchy of efficacy.
In the same family
Further entries in the curriculum
Sourcing · Independently verified
When you're ready, source thoughtfully.